Preferred Label : Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine;
NCIt definition : A cancer vaccine comprised of nine class I major histocompatibility complex (MHC)-restricted
breast cancer associated peptides, the tetanus toxoid helper peptide and the Toll-like
receptor 3 (TLR3) agonist poly ICLC, with potential immunostimulatory and antineoplastic
activities. The nine peptides derived from six cancer associated proteins are epidermal
growth factor receptor 2 (HER2/neu), carcinoembryonic antigen (CEA) and four cancer/testis
antigens (CTAs: MAGE-A1, -A3, -A10, and NY-ESO-1). Vaccination with this vaccine may
elicit a specific cytotoxic T-lymphocyte (CTL) response against cells overexpressing
these tumor associated antigens (TAAs). As a nonspecific T-helper epitope, tetanus
toxoid helper peptide binds to class II MHC and results in long-term immunopotentiation
by increasing the helper T-cell response. Poly ICLC, the double-stranded RNA molecules
of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose,
binds to TLR3 and induces the release of cytokines which may help boost the immune
response against the TAAs.;
NCI Metathesaurus CUI : CL434402;
Origin ID : C100099;
UMLS CUI : C3639091;
Semantic type(s)
- concept_is_in_subset
- has_target
